Regulatory approval

Published by the Health Canada. Approved

TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained >= 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering >= 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.

This is written in the approval document.

Citation

Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00082952.PDF. Revised December 2025. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
HC (1)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals